Log in

Relevant bibliographies by topics / Prognosis Serous carcinoma / Journal articles

To see the other types of publications on this topic, follow the link: Prognosis Serous carcinoma.

Journal articles on the topic 'Prognosis Serous carcinoma'

Author: Grafiati

Published: 5 June 2025

Last updated: 1 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Prognosis Serous carcinoma.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Seidman, Jeffrey D., Anna Yemelyanova, Jonathan A. Cosin, Anthony Smith, and Robert J. Kurman. "Survival Rates for International Federation of Gynecology and Obstetrics Stage III Ovarian Carcinoma by Cell Type: A Study of 262 Unselected Patients With Uniform Pathologic Review." International Journal of Gynecologic Cancer 22, no. 3 (2012): 367–71. http://dx.doi.org/10.1097/igc.0b013e31823c6f80.

Full text

Abstract:

ObjectivePublished data are conflicting on the influence of cell type on prognosis in ovarian cancer. The recent separation of low-grade serous carcinoma as a distinctive cell type of ovarian cancer with an indolent behavior, in retrospect, suggests that survival in studies that have not separated this group may be inaccurate.MethodsAn unselected series of 262 International Federation of Gynecology and Obstetrics stage III ovarian carcinomas was studied. Diagnostic classification of each tumor was made with particular attention to recent refinements in cell-type classification. Survival curves

APA, Harvard, Vancouver, ISO, and other styles

2

Dr., Dharani V. C., Manjunath H. K. Dr., Akshatha Basavaraju Dr., et al. "Histomorphological Pattern Analysis of Endometrial Carcinomas in a Tertiary Care Hospital." Advance Research Journal of Multidisciplinary Discoveries 73, no. 1 (2022): 01–07. https://doi.org/10.5281/zenodo.6785687.

Full text

Abstract:

<strong>Background: </strong>Endometrial carcinoma which has various histological types is the commonest invasive cancer of female genital tract. Two general groups of endometrial cancer include Type 1 and Type 2. Type 1 tumors are related to prolonged estrogenic stimulation and include endometrioid type and type 2 includes serous carcinoma, clear cell carcinoma and carcinosarcoma.   <strong>Materials and methods</strong>:  The present study is a retrospective study conducted in the department of pathology at BGS GIMS from January 2018- January 2021.  All the endometrial carcino

APA, Harvard, Vancouver, ISO, and other styles

3

Katagiri, Hiroshi, Kentaro Nakayama, Mohammed Tanjimur Rahman, et al. "Is ATP7B a Predictive Marker in Patients With Ovarian Carcinoma Treated With Platinum-Taxane Combination Chemotherapy?" International Journal of Gynecologic Cancer 23, no. 1 (2013): 60–64. http://dx.doi.org/10.1097/igc.0b013e318275afef.

Full text

Abstract:

ObjectiveThis study examined the prognostic significance of copper-transporting P-type adenosine triphosphatase (ATP7B) expression in patients with ovarian carcinoma treated with platinum-taxane combination chemotherapy.MethodsExpression of ATP7B in ovarian carcinoma was assessed by immunohistochemistry and clinical data collected by retrospective review of medical charts.ResultsOverexpression of ATP7B was identified in 25 (29.1%) of 86 ovarian carcinomas. The frequency of ATP7B expression in clear cell carcinomas was significantly higher than that in serous high-grade carcinomas (P< 0.05).

APA, Harvard, Vancouver, ISO, and other styles

4

Dergham, Ana Paula, Caroline Busatta Vaz de Paula, Seigo Nagashima, Márcia Olandoski, Lucia de Noronha, and Vanessa Santos Sotomaior. "Immunohistochemical Profiling of PD-1, PD-L1, CD8, MSI, and p53 and Prognostic Implications in Advanced Serous Ovarian Carcinoma: A Retrospective Study." Journal of Personalized Medicine 13, no. 7 (2023): 1045. http://dx.doi.org/10.3390/jpm13071045.

Full text

Abstract:

Advanced high-grade serous ovarian carcinoma is a serious malignant neoplasm with a late diagnosis and high mortality rate. Even when treated with standard therapy, such as surgery followed by carboplatin and paclitaxel chemotherapy, the prognosis remains unfavorable. Immunotherapy is a treatment alternative that requires further study. Therefore, we aimed to evaluate the expression of PD-1, PD-L1, CD8, MSI (MLH1, MSH2, MSH6, and PMS2), and p53 in the paraffin samples of high-grade serous ovarian carcinoma. A retrospective study of 28 southern Brazilian patients with advanced serous ovarian ca

APA, Harvard, Vancouver, ISO, and other styles

5

Kenda Šuster, Nataša, Snježana Frković Grazio, Irma Virant-Klun, Ivan Verdenik, and Špela Smrkolj. "Cancer Stem Cell–Related Marker NANOG Expression in Ovarian Serous Tumors: A Clinicopathological Study of 159 Cases." International Journal of Gynecologic Cancer 27, no. 9 (2017): 2006–13. http://dx.doi.org/10.1097/igc.0000000000001105.

Full text

Abstract:

ObjectiveThe objectives of this study were to assess cancer stem cell–related marker NANOG expression in ovarian serous tumors and to evaluate its prognostic significance in relation to ovarian serous carcinoma.MethodsNANOG protein expression was immunohistochemically evaluated in the ovarian tissue microarrays of 20 patients with benign ovarian serous tumors, 30 patients with borderline ovarian serous tumors, and 109 patients with ovarian serous carcinomas, from which 106 were of high-grade and 3 of low-grade morphology Immunohistochemical reaction was scored according to signal intensity and

APA, Harvard, Vancouver, ISO, and other styles

6

Vaziri Fard, Elmira, Sara Imboden, Tilman Rau, et al. "p53 Abnormal (Copy Number High) Endometrioid Endometrial Carcinoma Has a Prognosis Indistinguishable From Serous Carcinoma." International Journal of Gynecological Pathology 43, no. 5 (2024): 515–26. http://dx.doi.org/10.1097/pgp.0000000000001012.

Full text

Abstract:

Among the 4 molecular subgroups of endometrial carcinoma, the p53 abnormal (copy number high) subgroup has the worst prognosis; however, the histologic characteristics of this subgroup are not well established. Also, it is not well established whether low-grade tumors can belong to the p53 abnormal molecular subgroup and if so, what is the prognostic significance of the p53-mutated molecular subgroup in low-grade tumors. In the current study, we included 146 p53-mutated endometrial carcinomas and performed molecular subgrouping either based on a combination of immunohistochemical studies for p

APA, Harvard, Vancouver, ISO, and other styles

7

Jena, Saubhagya Kumar, Pritinanda Mishra, Vandana Mohapatra, and Sweta Singh. "Bilateral Serous Psammocarcinoma of Ovary: Rare Variant Low Grade Serous Carcinoma." Case Reports in Obstetrics and Gynecology 2015 (2015): 1–4. http://dx.doi.org/10.1155/2015/531242.

Full text

Abstract:

Serous psammocarcinoma is a rare variant of serous carcinoma arising from either ovary or peritoneum, characterized by massive psammoma body formation, low grade cytologic features, and invasiveness. Its clinical behavior is similar to serous borderline tumors with relatively favorable prognosis. We report herein a case of a 60-year-old postmenopausal woman who presented with abdominal distension. Contrast enhanced computed tomography (CECT) revealed calcified pelvic masses with ascites. Elevated serum CA-125 (970 U/mL) suggested malignant ovarian neoplasm. Patient underwent exploratory laparo

APA, Harvard, Vancouver, ISO, and other styles

8

Kimyon Cömert, Günsu, Burak Ersak, Abdurrahman Alp Tokalıoglu, et al. "Prognostic value of the presence of serous endometrial intraepithelial carcinoma in uterine serous carcinoma." Cukurova Medical Journal 49, no. 2 (2024): 239–47. http://dx.doi.org/10.17826/cumj.1392952.

Full text

Abstract:

Purpose: To investigate the clinical-pathological findings, prognosis, and survival outcome of uterine serous carcinoma (USC) with or without serous endometrial intraepithelial carcinoma (SEIC) which is still a rare entity in literature. Materials and Methods: A total of 98 patients with USC who underwent at least a hysterectomy were reviewed. After elimination for exclusion criteria, totally 76 patients with USC who had surgical staging were evaluated. SEIC was defined as the replacement of the surface and glands of the adjacent atrophic endometrium without invasion of the stroma by the highl

APA, Harvard, Vancouver, ISO, and other styles

9

Kalyani, R., Aparna Narasimha, ML Harendra Kumar, and S. Narayanswamy. "Extraovarian Papillary Serous Carcinoma of the Peritoneum: A Report of Two Cases with Review of Literature." Journal of South Asian Federation of Obstetrics and Gynaecology 5, no. 1 (2013): 42–44. http://dx.doi.org/10.5005/jp-journals-10006-1219.

Full text

Abstract:

ABSTRACT Extraovarian papillary serous carcinoma of the peritoneum is a rare malignancy characterized by peritoneal carcinomatosis presenting with abdominal pain and ascites. This tumor is similar to serous ovarian carcinoma in context to its clinical presentation, histologic appearance, pattern of spread, treatment and prognosis. We hereby report two cases of extraovarian papillary serous carcinoma of the peritoneum and review of literature. How to cite this article Kalyani R, Narasimha A, Kumar HML, Narayanswamy S. Extraovarian Papillary Serous Carcinoma of the Peritoneum: A Report of Two Ca

APA, Harvard, Vancouver, ISO, and other styles

10

Sagae, Satoru, Nobuyuki Susumu, Akila N. Viswanathan, et al. "Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine Serous Carcinoma." International Journal of Gynecologic Cancer 24, Supp 3 (2014): S83—S89. http://dx.doi.org/10.1097/igc.0000000000000264.

Full text

Abstract:

ObjectivesUterine serous carcinoma (USC) represents a rare and aggressive histologic subtype of endometrial cancer, associated with a poor prognosis. This article critically reviews the literature pertinent to the epidemiology, pathology, molecular biology, diagnosis, management, and perspectives of patients with USC.MethodsAs one of a series of The Gynecologic Cancer InterGroup (GCIG) Rare Tumor Working Group in London, November 2013, we discussed about USC many times with various experts among international GCIG groups.ResultsBoth USC and approximately 25% of high-grade endometrioid tumors r

APA, Harvard, Vancouver, ISO, and other styles

11

Punzón-Jiménez, Paula, Victor Lago, Santiago Domingo, Carlos Simón, and Aymara Mas. "Molecular Management of High-Grade Serous Ovarian Carcinoma." International Journal of Molecular Sciences 23, no. 22 (2022): 13777. http://dx.doi.org/10.3390/ijms232213777.

Full text

Abstract:

High-grade serous ovarian carcinoma (HGSOC) represents the most common form of epithelial ovarian carcinoma. The absence of specific symptoms leads to late-stage diagnosis, making HGSOC one of the gynecological cancers with the worst prognosis. The cellular origin of HGSOC and the role of reproductive hormones, genetic traits (such as alterations in P53 and DNA-repair mechanisms), chromosomal instability, or dysregulation of crucial signaling pathways have been considered when evaluating prognosis and response to therapy in HGSOC patients. However, the detection of HGSOC is still based on trad

APA, Harvard, Vancouver, ISO, and other styles

12

Kakimoto, Soichiro, Morikazu Miyamoto, Takahiro Einama, et al. "Co-Expression of Mesothelin and CA125 Is Associated with the Poor Prognosis of Endometrial Serous Carcinoma and Mixed Carcinomas Including Serous Carcinoma." Pathology & Oncology Research 26, no. 4 (2020): 2299–306. http://dx.doi.org/10.1007/s12253-020-00823-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Esen, Hasan, Gülay Turan, Hamdi Arbağ, and F. Cavide Sönmez. "Favorable Prognosis Variant Acinic Cell Carcinoma in Parotid Gland And Prognostic Parameters." European Journal of Therapeutics 16, no. 1 (2010): 23–25. http://dx.doi.org/10.58600/eurjther.2010-16-1-1318-arch.

Full text

Abstract:

Asinic cell carcinoma, previously known as 'acinic cell tumor'', is a neoplasm demostrating cytologic differentiation serous acinar cells. Differentiation sometimes only focally. This neoplasm does not show myoepitelial participation. The most frequent sites of occurence are the parotid gland. The most important prognostic indicators for acinic cell carcinoma are clinical stage and status of the resection margin. Frequent mitoses, high proliferative index (Ki67>%5), fokal necrosis, perineural invasion, gross invasion, desmoplasia, atypia and depletion of lymphocytes in the stroma have been

APA, Harvard, Vancouver, ISO, and other styles

14

Jayakumar, NM, PS Sangam, VU Grampurohit, and AF Myagery. "Primary Papillary Serous Carcinoma of the Peritoneum." Nepal Journal of Obstetrics and Gynaecology 8, no. 2 (2014): 60–62. http://dx.doi.org/10.3126/njog.v8i2.9774.

Full text

Abstract:

Primary papillary serous carcinoma of peritoneum (PPSCP) is a rare type of primary peritoneal adenocarcinoma and is clinico-histopathologically indistinguishable from primary ovarian papillary serous carcinoma. A 70 -year- female presented with pain abdomen of 4 months duration. On examination partially mobile vague mass was present in the suprapubic region. Exploratory laparotomy revealed normal right ovary and the left ovary showed simple cyst. Nodular, firm tumour was seen arising from omentum and measured 20x13x9.3 cm. Microscopically tumour was composed of large sheets of polygonal cells

APA, Harvard, Vancouver, ISO, and other styles

15

Rabban, Joseph T., and Charles J. Zaloudek. "Minimal uterine serous carcinoma: current concepts in diagnosis and prognosis." Pathology 39, no. 1 (2007): 125–33. http://dx.doi.org/10.1080/00313020601146814.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Chao, Kuan-Chong, Yi-Jen Chen, Chi-Mou Juang, et al. "Prognosis for advanced-stage primary peritoneal serous papillary carcinoma and serous ovarian cancer in Taiwan." Taiwanese Journal of Obstetrics and Gynecology 52, no. 1 (2013): 81–84. http://dx.doi.org/10.1016/j.tjog.2012.10.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Ham, Jonathan, Andi S. H. D. Nasser, Rina Masadah, et al. "A Retrospective Comparative Study of Clinicopathological Features in High-Grade and Low-Grade Serous Ovarian Carcinoma." Healthy Tadulako Journal (Jurnal Kesehatan Tadulako) 11, no. 1 (2025): 141–47. https://doi.org/10.22487/htj.v11i1.1558.

Full text

Abstract:

Backgroud: Ovarian carcinoma is the third most common malignancy in Indonesian women after breast and cervical cancer. Serous ovarian carcinoma is the most frequent subtype, divided into low-grade and high-grade types, each with distinct genetic and biological characteristics. Objective:This study aims to compare the clinicopathological features of high-grade and low-grade serous ovarian carcinoma. Methods: A retrospective cross-sectional study was conducted using 77 paraffin-embedded samples of serous ovarian carcinoma. Clinical and pathological data including age, body mass index (BMI), age

APA, Harvard, Vancouver, ISO, and other styles

18

Macwhinnie, N., and H. Monaghan. "The use of P53, PTEN, and C-erbB-2 to differentiate uterine serous papillary carcinoma from endometrioid endometrial carcinoma." International Journal of Gynecologic Cancer 14, no. 5 (2004): 938–46. http://dx.doi.org/10.1136/ijgc-00009577-200409000-00030.

Full text

Abstract:

Endometrial adenocarcinoma is the most common pelvic genital malignancy in the western world. The most common subtype of endometrial cancer is endometrioid endometrial carcinoma (EEC), which has a relatively good prognosis. Uterine serous papillary carcinoma (USPC) is also a subtype of endometrial carcinoma. This is an aggressive carcinoma with the majority of patients presenting at stage 3–4 and has a worse prognosis stage for stage when compared with EEC. In addition, the treatment of USPC is more extensive than that of EEC, and therefore definitive diagnosis before surgery ensures the optim

APA, Harvard, Vancouver, ISO, and other styles

19

Niogret, Julie, Valentin Derangère, Corentin Richard, et al. "Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological Cancer Harboring RAS Mutation: A Case Series." International Journal of Molecular Sciences 23, no. 6 (2022): 3343. http://dx.doi.org/10.3390/ijms23063343.

Full text

Abstract:

Low-grade serous carcinoma represents a minority of serous carcinoma. Although they have better prognosis than high-grade serous carcinoma, they respond poorly to chemotherapy. Thus, it appears necessary to find other treatments such as targeted therapies. Since RAS or RAF mutations occur frequently in low-grade serous carcinoma and lead to constitutively activated MAPK cascade, MEK inhibition should be effective in the treatment of low-grade serous carcinoma. So, we wanted to evaluate the clinical benefit of MEK inhibitors in the management of advanced-stage low-grade serous carcinoma harbori

APA, Harvard, Vancouver, ISO, and other styles

20

Clarke, Blaise A., and C. Blake Gilks. "Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type." Journal of Clinical Pathology 63, no. 5 (2010): 410–15. http://dx.doi.org/10.1136/jcp.2009.071225.

Full text

Abstract:

Histopathological assessment of tumour grade and cell type is central to the management of endometrial carcinoma, guiding the extent of surgery and the use of adjuvant radiation therapy and chemotherapy. Endometrioid carcinomas are usually low grade but high-grade examples are encountered, and they have a significantly worse prognosis, similar to that of high-grade subtypes such as serous and clear cell carcinoma. This article reviews the various grading systems that have been proposed for use with endometrioid endometrial carcinoma, and discusses the recent progress in cell type assignment, i

APA, Harvard, Vancouver, ISO, and other styles

21

Voutsadakis, Ioannis A. "Hormone Receptors in Serous Ovarian Carcinoma: Prognosis, Pathogenesis, and Treatment Considerations." Clinical Medicine Insights: Oncology 10 (January 2016): CMO.S32813. http://dx.doi.org/10.4137/cmo.s32813.

Full text

Abstract:

A few breakthroughs have been accomplished for the treatment of ovarian cancer, the most deadly gynecologic carcinoma, in the current era of targeted oncologic treatment. The estrogen receptor was the first target of such treatments with the introduction of tamoxifen four decades ago in breast cancer therapeutics. Attempts to duplicate the success of hormonal therapies in ovarian cancer met with mixed results, which may be due to an inferior degree of hormone dependency in this cancer. Alternatively, this may be due to the failure to clearly identify the subsets of ovarian cancer with hormone

APA, Harvard, Vancouver, ISO, and other styles

22

Nguyen, N. P., S. Sallah, U. Karlsson, et al. "Prognosis for papillary serous carcinoma of the endometrium after surgical staging." International Journal of Gynecological Cancer 11, no. 4 (2001): 305–11. http://dx.doi.org/10.1046/j.1525-1438.2001.011004305.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Dubernard, G., P. Morice, A. Rey, et al. "Prognosis of stage III or IV primary peritoneal serous papillary carcinoma." European Journal of Surgical Oncology (EJSO) 30, no. 9 (2004): 976–81. http://dx.doi.org/10.1016/j.ejso.2004.08.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

DUBERNARD, G., P. MORICE, A. REY, et al. "Prognosis of stage III or IV primary peritoneal serous papillary carcinoma." European Journal of Surgical Oncology 30, no. 9 (2004): 976–81. http://dx.doi.org/10.1016/s0748-7983(04)00233-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Semer, D., N. P. Nguyen, S. Sallah, et al. "Prognosis for papillary serous carcinoma of the endometrium after surgical staging." International Journal of Gynecologic Cancer 11, no. 4 (2001): 305–11. http://dx.doi.org/10.1136/ijgc-00009577-200107000-00009.

Full text

Abstract:

Abstract.Nguyen NP, Sallah S, Karlsson U, Vos P, Ludin A, Semer D, Tait D, Salehpour M, Jendrasiak G, Robiou C. for papillary serous carcinoma of the endometrium after surgical staging.Background: To investigate the pattern of failure and the prognosis following pathological staging for uterine papillary serous carcinoma (UPSC).Patients and methods: A retrospective review was conducted of 22 patients with UPSC, treated between 1989 and 1998 at a single institution. All patients were surgically staged. Two patients with advanced disease received chemotherapy only. Two patients with early-stage

APA, Harvard, Vancouver, ISO, and other styles

26

Oktem, Gulperi, Muzaffer Sanci, Ayhan Bilir, et al. "Cancer Stem Cell and Embryonic Development-Associated Molecules Contribute to Prognostic Significance in Ovarian Cancer." International Journal of Gynecologic Cancer 22, no. 1 (2012): 23–29. http://dx.doi.org/10.1097/igc.0b013e31823228b2.

Full text

Abstract:

ObjectivesEmbryonic molecules and cancer stem cell signaling resemble each other, and they organize cancer modality. We hypothesized that similar immunohistochemical expressions between tumor spheroids and patients’ samples compared with clinical relevance would give an important clue in patients’ prognosis.MethodsImmunohistochemical expression of c-kit, Notch1, Jagged1, and Delta1 in 50 cases of primary ovarian tumors (10 endometrioid, 10 serous, 10 mucinous adenocarcinoma, 10 borderline serous, and 10 borderline mucinous tumors) and MDAH-2774 spheroids were investigated. Results were compare

APA, Harvard, Vancouver, ISO, and other styles

27

Kim, Se Ik, Minsun Jung, Kisoon Dan, et al. "Proteomic Discovery of Biomarkers to Predict Prognosis of High-Grade Serous Ovarian Carcinoma." Cancers 12, no. 4 (2020): 790. http://dx.doi.org/10.3390/cancers12040790.

Full text

Abstract:

Initial identification of biomarkers predicting the exact prognosis of high-grade serous ovarian carcinoma (HGSOC) is important in precision cancer medicine. This study aimed to investigate prognostic biomarkers of HGSOC through proteomic analysis. We conducted label-free liquid chromatography-mass spectrometry using chemotherapy-naïve, fresh-frozen primary HGSOC specimens, and compared the results between a favorable prognosis group (progression-free survival (PFS) ≥ 18 months, n = 6) and a poor prognosis group (PFS < 18 months, n = 6). Among 658 differentially expressed proteins, 288 prot

APA, Harvard, Vancouver, ISO, and other styles

28

Ferriss, J. Stuart, Britt K. Erickson, Ie-Ming Shih, and Amanda N. Fader. "Uterine serous carcinoma: key advances and novel treatment approaches." International Journal of Gynecologic Cancer 31, no. 8 (2021): 1165–74. http://dx.doi.org/10.1136/ijgc-2021-002753.

Full text

Abstract:

The incidence and mortality rates from endometrial cancer continue to increase worldwide, while rates in most other cancers have either plateaued or declined considerably. Uterine serous carcinoma represents a fraction of all endometrial malignancies each year, yet this histology is responsible for nearly 40% of all endometrial cancer-related deaths. These deaths disproportionately affect black women, who have higher rates of advanced disease at diagnosis. Molecular genetic analyses reveal major alterations including TP53 mutation, PIK3CA mutation/amplification, ERBB2 amplification, CCNE1 ampl

APA, Harvard, Vancouver, ISO, and other styles

29

Živný, Jan H., S. Leahomschi, P. Klener, J. Živný, M. Haluzík, and D. Cibula. "Comparison of Plasma Osteopontin Levels between Patients with Borderline Ovarian Tumours and Serous Ovarian Carcinoma." Folia Biologica 62, no. 6 (2016): 258–62. http://dx.doi.org/10.14712/fb2016062060258.

Full text

Abstract:

Osteopontin (OPN) is a novel biomarker of various cancers including ovarian carcinoma. OPN is a promising adjunct to a major biomarker of ovarian cancer, CA125, in diagnosis, differential diagnosis and prognosis. The aim of our study was to measure the plasma level of OPN and CA125 in patients with borderline ovarian tumours (BOTs), serous ovarian carcinoma, and controls to determine its potential role in the differential diagnosis between serous ovarian carcinoma and BOT. The plasma samples of 66 women were analysed using Luminex technology, designed to simultaneously measure multiple specifi

APA, Harvard, Vancouver, ISO, and other styles

30

Jia, Wei, and Mengci Li. "Unveiling Insights into Ovarian Cancer Metabolism through Space- and Time-Resolved Analysis." Cancers 15, no. 19 (2023): 4881. http://dx.doi.org/10.3390/cancers15194881.

Full text

Abstract:

High-grade serous carcinoma (HGSC) represents a formidable challenge in the realm of ovarian cancer, notorious for its elusive early detection, poor prognosis and limited understanding of the intricacies of its pathogenesis [...]

APA, Harvard, Vancouver, ISO, and other styles

31

Svarna, Anna, Michalis Liontos, Alkistis Papatheodoridi, et al. "Molecular Prognostic Factors in Uterine Serous Carcinomas: A Systematic Review." Current Oncology 32, no. 5 (2025): 251. https://doi.org/10.3390/curroncol32050251.

Full text

Abstract:

Uterine serous carcinomas are an aggressive minority of endometrial cancers. They are characterized by mutations in TP53 and extensive copy number alterations and are primarily classified in the copy number-high/p53abn molecular prognostic group, highlighting a unique molecular profile that is crucial for understanding their behavior and treatment responses. Clinical studies have shown that molecular categorization via biomarkers can facilitate proper treatment selection, and this is now widely used. In this context, the scope of this systematic review is to identify molecular characteristics

APA, Harvard, Vancouver, ISO, and other styles

32

Yu, Xiaotang, Xinchen Zhang, Tie Bi, et al. "MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma." Tumor Biology 34, no. 6 (2013): 3501–8. http://dx.doi.org/10.1007/s13277-013-0928-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Kefeli, Aysegul Ucuncu, Busra Yaprak Bayrak, Esra Betul Tunce, et al. "Netrin-1 Expression in Uterine Serous Carcinoma and Its Association with Prognosis." Archives of Obstetrics and Gynaecology 4, no. 4 (2023): 91–98. http://dx.doi.org/10.33696/gynaecology.4.051.

Full text

Abstract:

Background/Objectives: Few biomarkers are used to predict the prognosis of serous uterine carcinoma (USC). Netrin-1, may be a promising biomarker candidate. Our aim was to investigate netrin-1 expression in USC tissues and analyze its relevance with disease prognosis. Material and Methods: The expression of netrin-1 in 48 USC patients’ tissues was examined by immunohistochemistry. Results: The overall netrin-1 positivity rate was 76%, detected as high expression in 17 (35%), and low expression in 19 (40%) of the patients. Patients suffering from tumors with no expression of netrin-1 (n= 15) ha

APA, Harvard, Vancouver, ISO, and other styles

34

Angelina, Yoan Alexandria, and Brahmana Askandar Tjokroprawiro. "Advanced Stage Clear Cell Ovarian Carcinoma Mimicking Uterine Sarcoma Without Gross Residual Tumor During Primary Surgery: A Case Report." Clinical Medicine Insights: Case Reports 16 (January 2023): 117954762311666. http://dx.doi.org/10.1177/11795476231166623.

Full text

Abstract:

Background: Clear cell ovarian carcinoma is rare and accounts for 1%-12% of ovarian epithelial carcinomas, depending on ethnicity. The prevalence of clear cell ovarian carcinoma in Asian, White, and Black women is 11.1%%, 4.8%, and 3.1%, respectively. Magnetic resonance imaging (MRI) shows that clear cell ovarian carcinomas are typically unilocular cyst-solid (34.9%) or multilocular-solid (41.4%); only 23.7% are solid with papillary projections. MRI can detect clear cell ovarian carcinoma with a sensitivity and specificity of 90% and 87%, respectively. Notably, sometimes ovarian masses have a

APA, Harvard, Vancouver, ISO, and other styles

35

Lin, Chih-kung, Her-Young Su, Wen-Chiuan Tsai, Lai-Fa Sheu, and Jong-Shiaw Jin. "Association of Cortactin, Fascin-1 and Epidermal Growth Factor Receptor (EGFR) Expression in Ovarian Carcinomas: Correlation with Clinicopathological Parameters." Disease Markers 25, no. 1 (2008): 17–26. http://dx.doi.org/10.1155/2008/284382.

Full text

Abstract:

Cortactin, fascin-1 and EGFR are recognized as important factors in tumor progression. We tested the hypothesis that cortactin, fascin-1 and EGFR expression correlates with clinicopathological parameters of the four most common ovarian surface epithelial carcinomas – serous cystadenocarcinoma, mucinous cystadenocarcinoma, endometrioid adenocarcinoma, and clear cell carcinoma. Immunohistochemical analysis of cortactin, fascin-1 and EGFR was performed using tissue microarrays of 172 specimens comprising 69 serous cystadenocarcinomas, 44 mucinous cystadenocarcinomas, 45 endometrioid adenocarcinom

APA, Harvard, Vancouver, ISO, and other styles

36

Bareiss, Petra M., Tanja N. Fehm, Anna Fischer, et al. "Aldehyde dehydrogenase activity in serous ovarian carcinoma." Journal of Clinical Oncology 30, no. 15_suppl (2012): e15577-e15577. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e15577.

Full text

Abstract:

e15577 Background: Only specific subpopulations of tumor cells, so called cancer stem cells (CSC) may initiate and maintain tumors. The phenotype and molecular properties of ovarian CSC remain elusive. Aldehyde dehydrogenase (ALDH) activity characterizes (cancer) stem cells in different tissues and has been associated with ovarian CSC (Silva et al, 2011; Kryczek et al, 2012). Contradictory results have been reported on ALDH1 expression and prognosis in ovarian carcinoma. In this study, we explore the role of ALDH in serous ovarian carcinoma (SOC). Methods: Aldefluor-staining was used to assess

APA, Harvard, Vancouver, ISO, and other styles

37

Arias-Diaz, Andrea Estrella, Miriam Ferreiro-Pantin, Jorge Barbazan, et al. "Ascites-Derived Organoids to Depict Platinum Resistance in Gynaecological Serous Carcinomas." International Journal of Molecular Sciences 24, no. 17 (2023): 13208. http://dx.doi.org/10.3390/ijms241713208.

Full text

Abstract:

Gynaecological serous carcinomas (GSCs) constitute a distinctive entity among female tumours characterised by a very poor prognosis. In addition to late-stage diagnosis and a high rate of recurrent disease associated with massive peritoneal carcinomatosis, the systematic acquisition of resistance to first-line chemotherapy based on platinum determines the unfavourable outcome of GSC patients. To explore the molecular mechanisms associated with platinum resistance, we generated patient-derived organoids (PDOs) from liquid biopsies of GSC patients. PDOs are emerging as a relevant preclinical mod

APA, Harvard, Vancouver, ISO, and other styles

38

Timmers, P. J., A. H. Zwinderman, I. Teodorovic, I. Vergote, and J. B. Trimbos. "Clear Cell Carcinoma Compared to Serous Carcinoma in Early Ovarian Cancer: Same Prognosis in a Large Randomized Trial." International Journal of Gynecologic Cancer 19, no. 1 (2009): 88–93. http://dx.doi.org/10.1111/igc.0b013e3181991546.

Full text

Abstract:

Background:An analysis was performed comparing survival of patients with clear cell carcinoma (CCC) to patients with serous adenocarcinoma (SAC) in early ovarian cancer. Furthermore, a literature search was done to clarify the clinical and histopathological features of clear cell tumors of the ovary.Methods:Between November 1990 and March 2000, 448 patients with ovarian cancer International Federation of Gynecology and Obstetrics stages I to IIa were enrolled in the European Organisation for Research and Treatment of Cancer-Adjuvant Chemotherapy in Ovarian Neoplasm Trial, a randomized study co

APA, Harvard, Vancouver, ISO, and other styles

39

Petrić-Miše, Branka, and Dinka Šundov. "A therapeutic approach to low-grade serous ovarian carcinoma." Libri Oncologici Croatian Journal of Oncology 48, no. 2-3 (2020): 109–15. http://dx.doi.org/10.20471/lo.2020.48.02-03.18.

Full text

Abstract:

Low-grade serous ovarian cancer (LGSOC) has less aggressive behavior and a better clinical outcome than high-grade serous ovarian cancer (HGSOC). Considering that this malignancy is relatively chemoresistant, surgery is the keystone of treatment, with a strong recommendation for maximal cytoreduction. Women with stage IA-IB disease should undergo observation alone after primary cytoreductive surgery. In contrast, observation, chemotherapy, or endocrine therapy are possible options for those with stage IC-IIA disease. Patients with stage IIB-IV disease receive either chemotherapy with carboplat

APA, Harvard, Vancouver, ISO, and other styles

40

Nasioudis, Dimitrios, Giovanni Sisti, Tomi T. Kanninen, Massimiliano Fambrini, and Mariarosaria Di Tommaso. "Prognostic Significance of Transitional Cell Carcinoma-Like Morphology of High-Grade Serous Ovarian Carcinoma: A Comparative Study." International Journal of Gynecologic Cancer 26, no. 9 (2016): 1624–29. http://dx.doi.org/10.1097/igc.0000000000000817.

Full text

Abstract:

ObjectivesThis was a retrospective population-based study investigating the demographic characteristics, clinical characteristics, and prognosis of patients with ovarian high-grade serous carcinoma displaying transitional cell carcinoma-like (TC-like) morphological features.Materials and MethodsA cohort of patients diagnosed with ovarian high-grade serous carcinoma from 1988 to 2012 was drawn from the National Cancer Institute's Surveillance Epidemiology and End Results Database. Patients with transitional cell histology were included in the study group, whereas patients with other serous tumo

APA, Harvard, Vancouver, ISO, and other styles

41

Iwahashi, Naoyuki, Midori Ikezaki, Masakazu Fujimoto, et al. "Lipid Droplet Accumulation Independently Predicts Poor Clinical Prognosis in High-Grade Serous Ovarian Carcinoma." Cancers 13, no. 20 (2021): 5251. http://dx.doi.org/10.3390/cancers13205251.

Full text

Abstract:

High-grade serous ovarian carcinoma (HGSOC) is an epithelial cancer that accounts for most ovarian cancer deaths. Metabolic abnormalities such as extensive aerobic glycolysis and aberrant lipid metabolism are well-known characteristics of cancer cells. Indeed, accumulation of lipid droplets (LDs) in certain types of malignant tumors has been known for more than 50 years. Here, we investigated the correlation between LD accumulation and clinical prognosis. In 96 HGSOC patients, we found that high expression of the LD marker adipophilin was associated with poor progression-free and overall survi

APA, Harvard, Vancouver, ISO, and other styles

42

Park, Ji Young, Joo-Hyun Nam, Young-Tak Kim, et al. "Poor prognosis of uterine serous carcinoma compared with grade 3 endometrioid carcinoma in early stage patients." Virchows Archiv 462, no. 3 (2013): 289–96. http://dx.doi.org/10.1007/s00428-013-1382-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Liu, Joyce, Amit M. Oza, Nicoletta Colombo, and Ana Oaknin. "ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma." International Journal of Gynecologic Cancer 32, no. 1 (2021): 89–92. http://dx.doi.org/10.1136/ijgc-2021-003144.

Full text

Abstract:

BackgroundUterine serous carcinoma is a distinct histologic subtype of endometrial cancer with an aggressive phenotype, poor prognosis, and limited therapeutic options. A previous proof-of-concept phase II trial of the Wee1 inhibitor adavosertib in uterine serous carcinoma demonstrated evidence of durable clinical activity.Primary ObjectiveTo evaluate the efficacy of adavosertib in women with recurrent or persistent uterine serous carcinoma.Study HypothesisWe hypothesize that adavosertib will demonstrate significant clinical activity, as measured by objective response rate, in women with recur

APA, Harvard, Vancouver, ISO, and other styles

44

Carbonnel, Marie, Laetitia Layoun, Marine Poulain, et al. "Serous Borderline Ovarian Tumor Diagnosis, Management and Fertility Preservation in Young Women." Journal of Clinical Medicine 10, no. 18 (2021): 4233. http://dx.doi.org/10.3390/jcm10184233.

Full text

Abstract:

Borderline ovarian tumors (BOT) represent about 10 to 20 percent of all epithelial tumors of the ovary. They constitute intermediate lesions between benign ovarian cysts and invasive carcinomas. They often occur in young women of reproductive age, and, albeit with a favorable prognosis, it may recur on the ipsilateral or contralateral ovary. Controversies surround the diagnostic criteria used for their assessment, and the optimal management to minimize their risk of recurrence and/or transformation into malignant carcinoma. Fertility preservation (FP) is considered a priority in the management

APA, Harvard, Vancouver, ISO, and other styles

45

Ihlow, Jana, Nanna Monjé, Inga Hoffmann, et al. "Low Expression of RGS2 Promotes Poor Prognosis in High-Grade Serous Ovarian Cancer." Cancers 14, no. 19 (2022): 4620. http://dx.doi.org/10.3390/cancers14194620.

Full text

Abstract:

RGS2 regulates G-protein signaling by accelerating hydrolysis of GTP and has been identified as a potentially druggable target in carcinomas. Since the prognosis of patients with high-grade serous ovarian carcinoma (HGSOC) remains utterly poor, new therapeutic options are urgently needed. Previous in vitro studies have linked RGS2 suppression to chemoresistance in HGSOC, but in situ data are still missing. In this study, we characterized the expression of RGS2 and its relation to prognosis in HGSOC on the protein level by immunohistochemistry in 519 patients treated at Charité, on the mRNA lev

APA, Harvard, Vancouver, ISO, and other styles

46

Murph, Mandi M., Wenbin Liu, Shuangxing Yu, et al. "Lysophosphatidic Acid-Induced Transcriptional Profile Represents Serous Epithelial Ovarian Carcinoma and Worsened Prognosis." PLoS ONE 4, no. 5 (2009): e5583. http://dx.doi.org/10.1371/journal.pone.0005583.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

d’Amati, Antonio, Federica Pezzuto, Gabriella Serio, et al. "Mesonephric-Like Carcinosarcoma of the Ovary Associated with Low-Grade Serous Carcinoma: A Case Report." Diagnostics 11, no. 5 (2021): 827. http://dx.doi.org/10.3390/diagnostics11050827.

Full text

Abstract:

Mesonephric adenocarcinomas are rare tumors of the female genital tract, thought to arise from embryonic mesonephric remnants, primarily in the cervix and vagina. Conversely, endometrial and ovarian mesonephric adenocarcinomas may have a different pathogenesis, probably originating from transdifferentiated Müllerian carcinomas, as demonstrated by the association of these neoplasms with endometriosis and ovarian serous tumors. For this reason, in the endometrium and in the ovary, they are defined as “mesonephric-like adenocarcinomas”. Some cases of mesonephric carcinomas of the female genital t

APA, Harvard, Vancouver, ISO, and other styles

48

Simons, Michiel, Nicole Ezendam, Johan Bulten, Iris Nagtegaal, and Leon Massuger. "Survival of Patients With Mucinous Ovarian Carcinoma and Ovarian Metastases: A Population-Based Cancer Registry Study." International Journal of Gynecologic Cancer 25, no. 7 (2015): 1208–15. http://dx.doi.org/10.1097/igc.0000000000000473.

Full text

Abstract:

ObjectivesPatients with mucinous ovarian carcinoma (MOC) generally have a favorable prognosis, although in advanced stage, prognosis is significantly worse compared to patients with serous ovarian carcinomas (SOCs). This might be due to the difficulties in distinguishing MOC from metastatic tumors. In the current study, we investigate prognosis of MOC compared to other types of ovarian cancer and to synchronous metastases to the ovary (sMO).Materials and MethodsAge, laterality, International Federation of Gynecology and Obstetrics stage, tumor grade, treatment, and survival were extracted from

APA, Harvard, Vancouver, ISO, and other styles

49

Chui, M. Herman, Jason C. Chang, Yanming Zhang, et al. "Spectrum of BRAF Mutations and Gene Rearrangements in Ovarian Serous Carcinoma." JCO Precision Oncology, no. 5 (September 2021): 1480–92. http://dx.doi.org/10.1200/po.21.00055.

Full text

Abstract:

PURPOSE Low-grade serous carcinoma (LGSC) is a rare type of ovarian cancer, which commonly arises from serous borderline tumor (SBT) and is characterized by frequent activating mutations in the mitogen-activated protein kinase pathway, including BRAF. The BRAFV600E mutation is associated with improved prognosis in SBT and LGSC, and responses to BRAF inhibitor therapy have been reported. We sought to characterize the clinicopathologic and molecular features of BRAF-driven tubo-ovarian and primary peritoneal serous tumors. METHODS Retrospective analysis of our institutional cohort of SBTs (n = 2

APA, Harvard, Vancouver, ISO, and other styles

50

Li, Wenhui, Lei Li, Ming Wu, Jinghe Lang, and Yalan Bi. "The Prognosis of Stage IA Mixed Endometrial Carcinoma." American Journal of Clinical Pathology 152, no. 5 (2019): 616–24. http://dx.doi.org/10.1093/ajcp/aqz083.

Full text

Abstract:

AbstractObjectivesTo explore the survival and definition of stage IA mixed endometrial carcinoma.MethodsFrom June 1, 2010, to June 1, 2017, cases with stage IA endometrial cancer were included in this study. The survival outcomes were compared among patients with endometrioid (group A), nonendometrioid (group B), and mixed subtypes (group C) and among patients with different proportions of nonendometrioid components (<5%, >50%, and others).ResultsIn total, 890 cases were included, comprising 808 (90.8%), 33 (3.7%), and 47 (5.3%) cases in groups A, B, and C, respectively. After a median f

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!